Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Zepbound, similar to Novo Nordisk’s anti-obesity and diabetes ... of the pulmonology division of the FDA’s drug evaluation center, called Friday’s approval “a major step forward for ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

LUPKIN: You know, it could, because the FDA just approved Zepbound as the first drug treatment for moderate to severe ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...